Newsletter | June 10, 2025

06.10.25 -- Understanding The Impact Of An RMP On Patient Risks Using Relational Risk Analysis

FEATURED EDITORIAL

Understanding The Impact Of An RMP On Patient Risks Using Relational Risk Analysis

Using relational risk analysis, let's take a closer look at risk management plans for identifying and managing adverse reactions for administering a new therapy to a patient.

INDUSTRY INSIGHTS

Utilizing A Stepwise Approach For Nitrosamine Risk Mitigation

The following insights and case studies demonstrate how a tailored, stepwise testing approach can effectively detect, quantify, and control nitrosamine impurities while maintaining cost efficiency.

Using Synthesis And Route Design Technology To Approach API Complexity

Leveraging computer-aided synthesis design technology and route scouting in the early stages of development can aid you in designing an efficient and cost-effective path to API manufacturing.

Improve Solubility And Spray Drying Throughput For Brick Dust Compounds

This paper presents three approaches to address poor solubility in organic solvents for spray drying as well as case studies outlining their successful application during development.

Meet Singota's 'Dr. Impossible'

Explore how Dr. Shehaab Savliwala, a leading formulation scientist at Singota Solutions, transforms complex pharmaceutical challenges into breakthroughs and innovative drug delivery.

Sinclair Nanopig For Biopharmaceuticals Safety Assessment

Discover groundbreaking data that supports the use of the Sinclair Nanopig to reduce reliance on traditional non-rodent species in drug development, validating its value in drug safety studies.

MOST POPULAR NEWS

Molecular Health & Axxam Enter Into A Strategic Partnership

Renovaro Secures Key U.S. Patent To Strengthen AI-Driven Drug Discovery

Technology Developed By ANBM To Be Utilized For New Drug Discovery Program

Tenpoint Therapeutics Ltd. Announces FDA Acceptance Of NDA For BRIMOCHOL PF

New NIST Standard Helps Deliver The Right Dosage Of Cancer-Fighting Drugs

ImmunAbs Announces FDA Phase 2 IND Approval Of IM-101

Bambusa Therapeutics Announces First Subject Dosed In Phase 1 Clinical Trial Of BBT002

BioNTech & BMS Announce Partnership To Develop Bispecific Antibody Candidate BNT327

Astellas Enters Exclusive License Agreement With Evopoint Biosciences For XNW27011

Kivu Bioscience Selects Sterling Pharma Solutions For cGMP Mfg Of Lead Oncology ADC KIVU-107

Orbis Medicines Accelerates Next-Gen Oral Macrocycle Platform With AI Capabilities Of Gefion Supercomputer

SOLUTIONS

A Cytokine Aids In Innate And Adaptive Immune Responses

Prometheus Panta C: Precision That Powers Biopharma Breakthroughs